2026-04-13T01:18:04Zhttps://recercat.cat/oai/request
oai:recercat.cat:2072/4695172024-11-04T06:09:49Zcom_2072_98col_2072_378192
RECERCAT author Zacarías-Fluck, Mariano F author Massó Vallés, Daniel author Giuntini, Fabio author González-Larreategui, Íñigo author Kaur, Jastrinjan author Casacuberta-Serra, Sílvia author Jauset, Toni author Martínez-Martín, Sandra author Martín-Fernández, Génesis author Serrano del Pozo, Erika author Foradada Felip, Laia author Grueso, Judit author Nonell, Lara author Beaulieu, Marie-Eve author Whitfield, Jonathan R. author Soucek, Laura author Universitat Autònoma de Barcelona 2024-11-04T06:09:49Z 2024-11-04T06:09:49Z 2023 http://hdl.handle.net/2072/469517 MYC's key role in oncogenesis and tumor progression has long been established for most human cancers. In melanoma, its deregulated activity by amplification of 8q24 chromosome or by upstream signaling coming from activating mutations in the RAS/RAF/MAPK pathway-the most predominantly mutated pathway in this disease-turns MYC into not only a driver but also a facilitator of melanoma progression, with documented effects leading to an aggressive clinical course and resistance to targeted therapy. Here, by making use of Omomyc, the most characterized MYC inhibitor to date that has just successfully completed a phase I clinical trial, we show for the first time that MYC inhibition in melanoma induces remarkable transcriptional modulation, resulting in severely compromised tumor growth and a clear abrogation of metastatic capacity independently of the driver mutation. By reducing MYC's transcriptional footprint in melanoma, Omomyc elicits gene expression profiles remarkably similar to those of patients with good prognosis, underlining the therapeutic potential that such an approach could eventually have in the clinic in this dismal disease. open access Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. https://creativecommons.org/licenses/by-nc/4.0/ Melanoma MYC Omomyc Signature Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma Article